Meridian Medical Technologies EpiPen
Executive Summary
Class I recall of 47 lots of EpiPen and EpiPen Jr. epinephrine auto-injectors initiated in U.S. and internationally because the devices "may not provide effective doses of medication to treat acute allergic emergencies," firm reports. No patients have been affected by the problem, which "arose in the process of advancing our automated production capabilities." The lots were distributed by Dey Labs between July and April